Teva announces positive results for schizophrenia treatment in Phase 3 trial

From GlobeNewswire: 2024-09-21 04:15:00

Teva Pharmaceuticals announced positive results for its Phase 3 SOLARIS trial evaluating TEV-‘749 for schizophrenia treatment. The study showed significant improvements in symptom severity and personal/social functioning compared to placebo. Importantly, there were no cases of Post-Injection Delirium/Sedation Syndrome (PDSS) in participants taking TEV-‘749. These findings suggest TEV-‘749 may offer a long-acting olanzapine option without the risk of PDSS. The data were presented at the 37th ECNP Congress in Milan, Italy. The results support the potential of TEV-‘749 to address unmet needs in treating schizophrenia, providing a safer alternative to current options.



Read more at GlobeNewswire: Teva Presents New Phase 3 Efficacy, Safety and Tolerability